pCDCAR1 CD19 h(ζDAP10)(CAR-MZ128)
The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a retroviral vector expressing scFv of anti-CD19 antibody linked to CD3ζ and DAP10 signaling domains. And the vector product was designed for the treatment of Acute lymphoblastic leukemia .
Targeting Cell Type
Acute lymphoblastic leukemia
Discription of Signaling Cassetes
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
DNAX-activating protein 10 (DAP10) is a transmembrane adaptor protein for natural killer group 2, member D (NKG2D), directly binds to RAGE and modulates the S100A8/A9-triggered signaling pathway. DAP10 as well as S100A8/A9 and RAGE were overexpressed in psoriatic epidermis.
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T cell surface antigen Leu-12; B-lymphocyte surface antigen B4; Chronic Lymphocytic Leukemia; CLL; scFv; CD28; Leukemia; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; FMC63
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Lenti-CD19 CAR (scFv-CD28-CD3ζ, S2) Viral Particle
||Anti-CD19 (FMC63) h(41BB-CD3ζ, K4/E4) Conditional CAR, pCDCAR1
||Anti-CD19 (105976) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 scFv h(CD4-CD3ζ) CARNK, pCDCAR1
||Anti-CD19 (47G4) h(CD28-CD27-FcεRIγ) CAR, pCDCAR1
||Anti-CD19 (FMC-63) h(t2B4-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-41BB-CD3ζ, S2) Viral Particle
||Anti-CD19 (Denintuzumab) h(41BB-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-41BB-CD3ζ, 105977) Viral Particle
||Anti-CD19 (47G4) h(CD28-CD3ζ) CAR, pCDCAR1